Use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies - Scientific guideline

HumanScientific guidelines

This document describes the basis and regulatory requirements for the use of minimal residue disease as an intermediate endpoint to predict clinical benefit in trials in chronic lymphocytic leukaemia.

Keywords: Minimal residual disease (MRD), chronic lymphocytic leukaemia (CLL)

Current effective version

Document history

Share this page